AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19570664 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric (LF)
Number of subjects: 150
Study 19570664 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 150
Study 18769356 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic antiretroviral therapy
Number of subjects: 883
Study 18769356 — intervention group
Group type: COMPARATOR
Intervention: Continuous antiretroviral therapy
Number of subjects: 883
Study 15730602 — intervention group
Group type: EXPERIMENTAL
Intervention: Infasurf (exogenous surfactant)
Number of subjects: 42
Study 15730602 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 42
Study 12053587 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonatory and respiratory function studies including MPT, MFR, PV, PQ, VVI
Number of subjects: 0
Study 12053587 — intervention group
Group type: EXPERIMENTAL
Intervention: Five physiologic criteria for laryngeal function evaluation
Number of subjects: 0
Study 10606323 — intervention group
Group type: EXPERIMENTAL
Intervention: CIFN 9 microg
Number of subjects: 472
Study 10606323 — intervention group
Group type: COMPARATOR
Intervention: IFN alpha‐2b 3 MU
Number of subjects: 472
Study 8984859 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.0625% with 2.5 micrograms.ml‐1 fentanyl
Number of subjects: 0
Study 8984859 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.125% alone
Number of subjects: 0
Study 1754638 — intervention group
Group type: EXPERIMENTAL
Intervention: Green light treatment (2 hours each morning for 1 week)
Number of subjects: 12
Study 1754638 — intervention group
Group type: EXPERIMENTAL
Intervention: White light treatment (2 hours each morning for 1 week)
Number of subjects: 12
Study 1754638 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence of treatment conditions
Number of subjects: 12
Study 7428802 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride 3.0 mg as sodium fluoride tablets during acid urine production (induced by NH4Cl)
Number of subjects: 5
Study 7428802 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride 3.0 mg as sodium fluoride tablets during alkaline urine production (obtained by NaHCO3)
Number of subjects: 5
Study 7428802 — intervention group
Group type: COMPARATOR
Intervention: Control experiments without F administrations
Number of subjects: 5
Study 31238808 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 124
Study 31238808 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab
Number of subjects: 124
Study 31083046 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument-assisted soft tissue mobilization (IASTM) for 5 minutes targeting the gastrocnemii, soleus, tibialis posterior muscles, deep fascia, and Achilles tendon.
Number of subjects: 14
Study 31083046 — intervention group
Group type: COMPARATOR
Intervention: Control condition (rest for 5 minutes without IASTM).
Number of subjects: 14
Study 28586162 — intervention group
Group type: EXPERIMENTAL
Intervention: DP10-60 ITF (8 g/day)
Number of subjects: 40
Study 28586162 — intervention group
Group type: EXPERIMENTAL
Intervention: DP2-25 ITF (8 g/day)
Number of subjects: 40
Study 28586162 — intervention group
Group type: COMPARATOR
Intervention: Fructose placebo (8 g/day)
Number of subjects: 40
Study 26453560 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 200
Study 26453560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 23325283 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA+HS (hypertonic saline-enhanced radiofrequency)
Number of subjects: 40
Study 23325283 — intervention group
Group type: COMPARATOR
Intervention: TACE+RFA (transarterial chemoembolization followed by radiofrequency)
Number of subjects: 40
Study 23325283 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA+HS
Number of subjects: 40
Study 23325283 — intervention group
Group type: COMPARATOR
Intervention: TACE+RFA
Number of subjects: 40
Study 17257231 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) infusion (0.5 microg/kg/min for 20 min)
Number of subjects: 12
Study 17257231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15036742 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (32-34 degrees C)
Number of subjects: 15
Study 15036742 — intervention group
Group type: COMPARATOR
Intervention: Normothermic therapy
Number of subjects: 15
Study 10660238 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA solution of 0.0625% bupivacaine and fentanyl 2 microg/mL (4 mL demand bolus, 15 min lockout) with clonidine 4.5 microg/mL (group BFC)
Number of subjects: 75
Study 10660238 — intervention group
Group type: COMPARATOR
Intervention: PCEA solution of 0.0625% bupivacaine and fentanyl 2 microg/mL (4 mL demand bolus, 15 min lockout) without clonidine (group BF)
Number of subjects: 75
Study 9303508 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus interferon (CIFN) 9 microg
Number of subjects: 704
Study 9303508 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus interferon (CIFN) 3 microg
Number of subjects: 704
Study 9303508 — intervention group
Group type: COMPARATOR
Intervention: Recombinant interferon alfa-2b (IFN-alpha2b) 15 microg
Number of subjects: 704
Study 8346818 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.7%)
Number of subjects: 38
Study 8346818 — intervention group
Group type: COMPARATOR
Intervention: Enflurane (0.9%)
Number of subjects: 38
Study 2871945 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA (500 mg b.i.d. for 6 months)
Number of subjects: 227
Study 2871945 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + MPA
Number of subjects: 227
Study 2871945 — intervention group
Group type: COMPARATOR
Intervention: CT + placebo
Number of subjects: 227
Study 2871945 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA
Number of subjects: 227
Study 30591153 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement
Number of subjects: 210
Study 30591153 — intervention group
Group type: COMPARATOR
Intervention: Light-cured composite
Number of subjects: 210
Study 29522149 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Number of subjects: 26
Study 26274985 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nimodipine (1-2 mg/hr) and hydroxyethyl starch (hematocrit 30%-35%) from the day before surgery until the 7th postoperative day
Number of subjects: 112
Study 26274985 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic treatment)
Number of subjects: 112
Study 26274985 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nimodipine (1-2 mg/hr) and hydroxyethyl starch (hematocrit 30%-35%)
Number of subjects: 112
Study 25511185 — intervention group
Group type: EXPERIMENTAL
Intervention: App-delivered relaxation techniques (autogenic training, mindfulness meditation, or guided imagery) practiced at least 5 days/week for 15 minutes/day over 6 months.
Number of subjects: 220
Study 25511185 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 220
Study 23268821 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportal TransFix®
Number of subjects: 168
Study 23268821 — intervention group
Group type: COMPARATOR
Intervention: Transtibial TransFix®
Number of subjects: 168
Study 19023152 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose abciximab (0.20 mg/kg bolus followed by 12-h infusion)
Number of subjects: 973
Study 19023152 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose abciximab (0.25 mg/kg bolus followed by 12-h infusion)
Number of subjects: 973
Study 19023152 — intervention group
Group type: COMPARATOR
Intervention: Placebo (bolus and infusion of placebo)
Number of subjects: 973
Study 17227669 — intervention group
Group type: EXPERIMENTAL
Intervention: merthiolated antigen
Number of subjects: 400
Study 17227669 — intervention group
Group type: EXPERIMENTAL
Intervention: phenolated antigen
Number of subjects: 400
Study 17227669 — intervention group
Group type: COMPARATOR
Intervention: merthiolated saline
Number of subjects: 400
Study 17227669 — intervention group
Group type: COMPARATOR
Intervention: phenolated saline
Number of subjects: 400
Study 16194314 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation of intercostobrachial nerve
Number of subjects: 162
Study 16194314 — intervention group
Group type: COMPARATOR
Intervention: No preservation of intercostobrachial nerve (Control)
Number of subjects: 162
Study 11927177 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 179
Study 11927177 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 179
Study 11927177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 9456098 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 230
Study 9456098 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aprotinin
Number of subjects: 230
Study 7702228 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐α2b
Number of subjects: 552
Study 2242740 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso‐Giuliani 3 1 and 4 1
Number of subjects: 191
Study 2242740 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso‐Giuliani 2 1
Number of subjects: 191
Study 2242740 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso‐Giuliani
Number of subjects: 191
Study 2242740 — intervention group
Group type: COMPARATOR
Intervention: Standard preparation
Number of subjects: 191
Study 362234 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 0
Study 31930338 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 0
Study 31930338 — intervention group
Group type: COMPARATOR
Intervention: Not experiencing a CVD event
Number of subjects: 0
Study 31930338 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCVD risk tertiles
Number of subjects: 0
Study 31151245 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 1036
Study 31151245 — intervention group
Group type: EXPERIMENTAL
Intervention: WC
Number of subjects: 1036
Study 31151245 — intervention group
Group type: EXPERIMENTAL
Intervention: WHtR
Number of subjects: 1036
Study 31151245 — intervention group
Group type: EXPERIMENTAL
Intervention: WHtR(exp)
Number of subjects: 1036
Study 28053257 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee joint distraction (KJD)
Number of subjects: 60
Study 28053257 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 60
Study 25387805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep hygiene and artificial bright light interventions
Number of subjects: 13
Study 25387805 — intervention group
Group type: COMPARATOR
Intervention: Control (no interventions)
Number of subjects: 13
Study 23494021 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation group (NS)
Number of subjects: 250
Study 23494021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance group (US)
Number of subjects: 250
Study 23494021 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation subgroup NS1
Number of subjects: 250
Study 23494021 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation subgroup NS2
Number of subjects: 250
Study 23494021 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation subgroup NS3
Number of subjects: 250
Study 21046232 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs)
Number of subjects: 82
Study 21046232 — intervention group
Group type: COMPARATOR
Intervention: No aromatase inhibitors (no AIs)
Number of subjects: 82
Study 19081397 — intervention group
Group type: EXPERIMENTAL
Intervention: 600-mg loading dose of clopidogrel
Number of subjects: 256
Study 19081397 — intervention group
Group type: COMPARATOR
Intervention: 300-mg loading dose of clopidogrel
Number of subjects: 256
Study 17955563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression model for cause-specific hazard
Number of subjects: 0
Study 17955563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine and Gray regression model for subdistribution hazard
Number of subjects: 0
Study 16390629 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient sprinkles containing 30 mg Fe/day
Number of subjects: 102
Study 16390629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 11276275 — intervention group
Group type: EXPERIMENTAL
Intervention: Potent pancreatic enzyme supplement (4 capsules with meals, 2 with snacks; lipase 10,000 USP units, protease 37,500 units, amylase 33,200 units)
Number of subjects: 29
Study 11276275 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after enzyme supplementation)
Number of subjects: 29
Study 11276275 — intervention group
Group type: EXPERIMENTAL
Intervention: Active enzyme supplementation (after placebo)
Number of subjects: 29
Study 9624697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracanalicular silicone plugs
Number of subjects: 35
Study 9624697 — intervention group
Group type: EXPERIMENTAL
Intervention: Rewetting drops with plugs
Number of subjects: 35
Study 9624697 — intervention group
Group type: EXPERIMENTAL
Intervention: Rewetting drops
Number of subjects: 35
Study 9624697 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (control)
Number of subjects: 35
Study 7933491 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (EP) 0.15 mg.kg‐1
Number of subjects: 30
Study 7933491 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (PH) 2 micrograms.kg‐1
Number of subjects: 30
Study 7933491 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EP and PH)
Number of subjects: 30
Study 2851177 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine and cisplatin (VP)
Number of subjects: 233
Study 2851177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin, and cisplatin (CAP)
Number of subjects: 233
Study 2851177 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 233
Study 29208402 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright position
Number of subjects: 110
Study 29208402 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 110
Study 27625146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg, local submucosal injection)
Number of subjects: 60
Study 27625146 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution, local submucosal injection)
Number of subjects: 60
Study 25080594 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation to altered auditory feedback
Number of subjects: 0
Study 25080594 — intervention group
Group type: COMPARATOR
Intervention: Auditory feedback that subjects received during learning
Number of subjects: 0
Study 23064980 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT)
Number of subjects: 20
Study 23064980 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Handgrip Exercise (HG)
Number of subjects: 20
Study 20940690 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with carnitine, acetyl carnitine, L-arginine and ginseng
Number of subjects: 180
Study 20940690 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 180
Study 18095903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 6560
Study 18095903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6560
Study 15876900 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg twice daily)
Number of subjects: 21
Study 15876900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 12522383 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatology Life Quality Index
Number of subjects: 257
Study 12522383 — intervention group
Group type: EXPERIMENTAL
Intervention: Work Productivity and Activity Impairment questionnaire
Number of subjects: 257
Study 11305547 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 2 g suppository
Number of subjects: 273
Study 11305547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study 9369820 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily gentamicin (4 mg/kg IV every 24 hours) with twice-daily clindamycin (1200 mg IV every 12 hours)
Number of subjects: 272
Study 9369820 — intervention group
Group type: COMPARATOR
Intervention: Thrice-daily gentamicin (1.33 mg/kg IV every 8 hours) with clindamycin (800 mg IV every 8 hours)
Number of subjects: 272
Study 9369820 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily gentamicin with twice-daily clindamycin
Number of subjects: 272
Study 9369820 — intervention group
Group type: COMPARATOR
Intervention: Thrice-daily gentamicin with clindamycin
Number of subjects: 272
Study 9369820 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 272
Study 1578946 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly myelosuppressive maintenance for 3 years after initial TAD treatment in the 1981 study.
Number of subjects: 674
Study 1578946 — intervention group
Group type: EXPERIMENTAL
Intervention: Second induction course for all patients up to 60 years of age in the 1985 study.
Number of subjects: 674
Study 1578946 — intervention group
Group type: COMPARATOR
Intervention: Auto-BMT in first complete remission (CR) as per the 1985 protocol.
Number of subjects: 674
Study 6738937 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting prostaglandin suppository (9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2)
Number of subjects: 95
Study 6738937 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 95
Study 31101439 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted Mediterranean diet
Number of subjects: 6646
Study 31101439 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher educational level
Number of subjects: 6646
Study 31101439 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smoking lifestyle
Number of subjects: 6646
Study 31101439 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of sedentary lifestyles
Number of subjects: 6646
Study 31478290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuminum cyminum L. essential oil (CuEO) 75 mg, thrice daily for 8 weeks
Number of subjects: 56
Study 31478290 — intervention group
Group type: COMPARATOR
Intervention: Placebo soft gel, thrice daily for 8 weeks
Number of subjects: 56
Study 25546488 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary group-based rehabilitation program plus oral medication
Number of subjects: 146
Study 25546488 — intervention group
Group type: COMPARATOR
Intervention: Oral medication alone
Number of subjects: 146
Study 25546488 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary group-based rehabilitation program
Number of subjects: 146
Study 24880917 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance and technique training
Number of subjects: 28
Study 24880917 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 28
Study 23680986 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience Corps™ (senior volunteer roles)
Number of subjects: 0
Study 23680986 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience Corps™ (for children)
Number of subjects: 0
Study 23680986 — intervention group
Group type: COMPARATOR
Intervention: Usual volunteering opportunities (control for older adults)
Number of subjects: 0
Study 23680986 — intervention group
Group type: COMPARATOR
Intervention: Matched, eligible control schools (control for children)
Number of subjects: 0
Study 20868637 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 140
Study 20868637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 19246733 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 9
Study 19246733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephradine (500 mg)
Number of subjects: 9
Study 19246733 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril and Cephradine co-administration
Number of subjects: 9
Study 17122621 — intervention group
Group type: EXPERIMENTAL
Intervention: Early nasogastric enteral nutrition (EN)
Number of subjects: 50
Study 17122621 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 50
Study 12648302 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine Purite 0.15% BID
Number of subjects: 407
Study 12648302 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine 0.2% BID
Number of subjects: 407
Study 10505743 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN therapy
Number of subjects: 24
Study 8726600 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with lovastatin 20 mg/day and niacin 500 mg 3 times/day
Number of subjects: 28
Study 8726600 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin 40 mg/day
Number of subjects: 28
Study 8726600 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin 20 mg/day
Number of subjects: 28
Study 2011669 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month rehabilitation programme
Number of subjects: 116
Study 2011669 — intervention group
Group type: COMPARATOR
Intervention: Routine cardiac follow-ups
Number of subjects: 116
Study 7302311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (not specified in detail)
Number of subjects: 160
Study 6465160 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (2,400 and 3,900 mg/day)
Number of subjects: 843
Study 6465160 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (1,200 mg/day)
Number of subjects: 843
Study 6465160 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (2,400 mg/day)
Number of subjects: 843
Study 6465160 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1,600 mg/day for three days)
Number of subjects: 843
Study 6465160 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (4,800 mg/day)
Number of subjects: 843
Study 6465160 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen, tolmetin sodium, indomethacin (larger doses)
Number of subjects: 843
Study 6465160 — intervention group
Group type: COMPARATOR
Intervention: Placebo, pro drugs, enteric-coated aspirin
Number of subjects: 843
Study 29315944 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline mouth rinse regimen and education programme
Number of subjects: 91
Study 29315944 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 91